Abecma — Total Revenues
Bristol-Myers Squibb Abecma — Total Revenues increased by 57.5% to $137.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $124.00M to $137.00M. Over 3 years (FY 2021 to FY 2024), Abecma — Total Revenues shows an upward trend with a 35.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and clinical adoption of the therapy, while a decrease may signal increased competition or challenges in patient access and manufacturing scalability.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Abecma, a B-cell maturation an...
Peer comparison
Comparable to specialized oncology product revenue lines or cell therapy segment sales reported by major pharmaceutical and biotechnology peers.
bmy_segment_abecma_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $24.00M | $71.00M | $69.00M | $67.00M | $89.00M | $107.00M | $125.00M | $147.00M | $132.00M | $93.00M | $100.00M | $82.00M | $95.00M | $124.00M | $105.00M | $103.00M | $87.00M | $137.00M |
| QoQ Change | — | +195.8% | -2.8% | -2.9% | +32.8% | +20.2% | +16.8% | +17.6% | -10.2% | -29.5% | +7.5% | -18.0% | +15.9% | +30.5% | -15.3% | -1.9% | -15.5% | +57.5% |
| YoY Change | — | — | — | — | +270.8% | +50.7% | +81.2% | +119.4% | +48.3% | -13.1% | -20.0% | -44.2% | -28.0% | +33.3% | +5.0% | +25.6% | -8.4% | +10.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's abecma — total revenues?
- Bristol-Myers Squibb (BMY) reported abecma — total revenues of $137.00M in Q3 2025.
- How has Bristol-Myers Squibb's abecma — total revenues changed year-over-year?
- Bristol-Myers Squibb's abecma — total revenues increased by 10.5% year-over-year, from $124.00M to $137.00M.
- What is the long-term trend for Bristol-Myers Squibb's abecma — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's abecma — total revenues has grown at a 35.3% compound annual growth rate (CAGR), from $164.00M to $406.00M.
- What does abecma — total revenues mean?
- Total revenue generated from the sale of the Abecma cell therapy product.